ClinicalTrials.gg
RecruitingNCT07657286interventionUpdated Jun 18, 2026

Inflammatory Cytokines and Oxidative Stress Biomarkers in Diabetic Chronic Kidney Disease Patients

An interventional study of aerobic treadmill exercises in Chronic Kidney Disease and Diabetes, sponsored by Badr University. Recruiting at 1 site in Egypt. Open to participants aged 36 Years to 58 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Badr University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
36 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Planned enrollment
23rd of 44
60 · median 64
Started
2026
with 8 others
No phase
23 of 64
5 open now
Primary completion
2026-09
later than 19 of 27 live
Registered
61st of 64
by date
Lead sponsor
3 of 64
Badr University

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 23rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, reaches primary completion later than 19 of the 27 other live ones, and was the 61st registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 36 Years to 58 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

This research intends to analyze how a 12-week adjustment in lifestyle influences inflammatory cytokines and oxidative stress indicators in overweight individuals diagnosed with type 2 diabetes and moderate CKD

Read the detailed description

: 60 patients, mostly sedentary, aged 36-58 years, were diagnosed with stages 3 and 4 chronic kidney disease (eGFR 25 to 60 ml/min/1.73 m²) with concomitant type 2 diabetes and indicated body mass indexes (BMI) between 30 to 35 kg/m². The subjects were randomly assigned to two unique groups: Intervention group (Group A): Participants completed supervised aerobic treadmill exercises while sticking to a calorie-limited diet (1200 kcal/day) throughout a 12-week period. Control group (Group B): Participants received standard nephrology care without any alterations in lifestyle. In the initial phases, there was a detailed analysis of biomarkers which was later confirmed in a review conducted at the 12-week mark focusing on TNF-α, IL-6, sCRP, CD, MDA, GSH, GPx, and SOD.

03

Conditions studied

  • Chronic Kidney Disease
  • Diabetes

Keywords

  • Diabetes; Weight Reduction; Oxidative Stress; Cytokines; Obesity.
04

Who can participate

Ages eligible
36 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • sedentary lifestyle for at least three months prior to enrollment
  • (BMI) of 30-35 kg/m².

Exclusion criteria

Exclusion Criteria:

  • using tobacco
  • heart failure
  • coronary arteries
  • severe heart valve problems
  • pregnant
  • liver inflammation
  • kidney transplant
  • physical injuries restricting them from exercising
  • utilization of anti-inflammatory medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    (Group A)

    Participants completed supervised aerobic treadmill exercises while sticking to a calorie-limited diet (1200 kcal/day) throughout a 12-week period.

    Other: aerobic treadmill exercises

  • No intervention
    group (B)

    Participants received standard nephrology care without any alterations in lifestyle.

Interventions

  • Otheraerobic treadmill exercises

    diet (1200 kcal/day)

    Also known as: a calorie-limited diet (1200 kcal/day)

06

What researchers measure

Primary outcomes

  1. MDA

    malondialdehyde

    Time frame: at baseline and after 12 WEEKS

  2. GSH

    Glutathione

    Time frame: at baseline and after 12 WEEKS

  3. GPx

    Glutathione peroxidase

    Time frame: at baseline and after 12 WEEKS

  4. SOD

    Superoxide dismutase

    Time frame: at baseline and after 12 WEEKS

  5. IL-6

    Interleukin-6

    Time frame: at baseline and after 12 WEEKS

  6. TNF-α

    tumor necrosis factor alpha

    Time frame: at baseline and after 12 WEEKS

  7. CRP

    C-reactive protein

    Time frame: at baseline and after 12 WEEKS

Secondary outcomes

  1. BMI

    Body mass index

    Time frame: at baseline and after 12 WEEKS

07

Study locations

1 of 1 sites recruiting
  • Mona Mohamed Abdelkhalek
    Cairo, Egypt
    Recruiting
    • Mona Mohamed Abdelkhalek, assistance prof · Contact3m.sons@gmail.com · 002021024056108
    • Mona mohamed Abdekhalek, assistance prof · Contact01024056108
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2026, 3 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 3 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2026
First posted
Jun 18, 2026
StartActual
Jun 7, 2026
Primary completionEst.
Sep 7, 2026
CompletionEst.
Sep 7, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07657286
Lead sponsor
Badr University
Responsible party
Mona Mohamed Abdelkhalek (assistance professor, Badr University) — Principal investigator
First posted
Jun 18, 2026
Start date
Jun 7, 2026
Primary completion
Sep 7, 2026 (estimated)
Completion
Sep 7, 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Mona Mohamed Abdelkhalek, assistance professor
Contact
3m.sons@gmail.com
00201024056108
Mona Mohamed Abdelkhalek, assistance professor
Contact
mona.abdelkhalek@buc.edu.eg
00201024056108
Mona Mohamed Abdelkhalek
principal investigator · Badr University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion